Evidence map›Paper›PMID 24614127›Full record

ArticleJournal of pediatric gastroenterology and nutrition2014

Pentavalent rotavirus vaccine in infants with surgical gastrointestinal disease.

Eric J McGrath, Ron Thomas, Christopher Duggan, Basim I Asmar

Abstract readControlled Clinical TrialMulticenter Study
In one paragraph

Article in Journal of pediatric gastroenterology and nutrition, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 2 pooled it
0.2field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 2 syntheses or guidelines pooled it, 15 citations in OpenAlex.

  1. Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2019
    Pooled it
  2. Vaccines for preventing rotavirus diarrhoea: vaccines in use.The Cochrane database of systematic reviews · 2019
    Pooled it
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eric J McGrath*Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine †Division of Gastroenterology, Hepatology and Nutrition, Boston Children's Hospital, Boston, MA.
Ron Thomas
Christopher Duggan
Basim I Asmar
Wayne State University · USBoston Children's Hospital · US

Funding

Patient-oriented Research in Pediatric Diarrheal DiseasesK24HD058795 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI DUGGAN, CHRISTOPHER P · 2010 to 2014
$956k
NICHD NIH HHS K24 HD058795NICHD NIH HHS K24HD058795
6 · The paper itself

Abstract

objectivesPentavalent rotavirus vaccine (RV5) has been shown to be well-tolerated and efficacious in preventing rotavirus gastroenteritis in healthy infants. Safety and immunogenicity of RV5 in infants with surgical gastrointestinal disease have not been studied. The aim of the present study was to evaluate the safety and immunogenicity of RV5 in infants with a history of congenital or acquired intestinal disease requiring resection compared with healthy infants.

methodsInfants with intestinal resection were matched by gestational age and chronological age to healthy infants (controls). Dose 1 of RV5 was given at 10 to 12 weeks of chronological age. Doses 2 and 3 were given at intervals of 4 to 10 weeks, with all 3 doses given by 32 weeks. All infants were monitored for adverse events (AEs) by telephone calls, clinic visits, and parental written reports during the first 42 days after each dose and monthly thereafter by telephone for 12 months. Serum anti-rotavirus immunoglobulin A (IgA) titers were measured prevaccination and 2 weeks after dose 3.

resultsA total of 5 infants with surgical gastrointestinal disease and 3 control subjects were enrolled. All participants (100%) mounted a 3-fold increase in serum anti-rotavirus IgA geometric mean titer postvaccination. RV5 administration to surgical infants was well tolerated with a majority of AEs being attributed to the underlying medical condition.

conclusionsPostvaccination serum anti-rotavirus IgA levels indicate that RV5 is immunogenic in infants with a history of bowel resection, despite varying lengths of residual bowel. RV5 was well tolerated with few vaccine-related AEs.

Indexed as

Antibodies, ViralCase-Control StudiesFemaleGastroenteritisHumansImmunization ScheduleImmunoglobulin AInfantIntestinal DiseasesMalePilot ProjectsProspective StudiesRotavirusRotavirus InfectionsRotavirus VaccinesVaccines, AttenuatedAntibodies, ViralImmunoglobulin ARotaTeqRotavirus VaccinesVaccines, Attenuated

Identifiers

PMID24614127
PMCPMC4624282
OpenAlexW2314558984

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.